Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cordis Webster

This article was originally published in The Gray Sheet

Executive Summary

Additional indications for the Celsius 6 and 7 Fr. temperature ablation catheters are approved Jan. 26 via premarket approval application supplement. The Johnson & Johnson unit's deflectable tip catheters are the first to gain U.S. clearance for the pediatric market and can be used on patients age four and older. Other indications include the interruption of accessory atrioventricular (AV) pathways associated with persistent junctional reciprocating tachycardia (PJRT), and treatment of Mahaim fibers, a congenital anomaly that creates accessory conduction pathways
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel